
Sign up to save your podcasts
Or


Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers
By Axios4.3
689689 ratings
Hydroxychloroquine has evolved from a sleepy anti-malaria drug into a partisan litmus test over the future of COVID-19 treatment. Dan and Axios healthcare reporter Bob Herman dig into what we know about the drug, what we still don't, and why both matter.
PLUS: New money for small businesses and a way to help New York medical workers

32,246 Listeners

30,609 Listeners

8,801 Listeners

26,380 Listeners

113,121 Listeners

56,944 Listeners

10,331 Listeners

5,217 Listeners

6,097 Listeners

561 Listeners

5,610 Listeners

10,254 Listeners

6,462 Listeners

2,020 Listeners

5,576 Listeners

4,365 Listeners

16,525 Listeners